Ketamine for Older Adults Pilot
Brief Summary
This pilot study will assess the safety and feasibility of intravenous (IV) ketamine in older adults with Treatment-Resistant Depression (TRD). In addition, this study will develop and utilize innovative methodological approaches to demonstrate the feasibility of precision medicine and mobile health approaches in depression treatment.
Condition or Disease
- Treatment Resistant Depression
- Refractory Depression
- Therapy-Resistant Depression
- Late Life Depression
- Geriatric Depression
Phase
Study Design
| Study type: | Interventional |
|---|---|
| Status: | Not yet recruiting |
| Study results: | No Results Available |
| Age: | 65 Years and older (Older Adult) |
| Enrollment: | 30 () |
| Funded by: | Other |
Masking |
|
Clinical Trial Dates
| Start date: | Sep 20, 2020 | |
|---|---|---|
| Primary Completion: | Sep 21, 2020 | |
| Completion Date: | Jan 22, 2020 | |
| Study First Posted: | Aug 07, 2020 | |
| Results First Posted: | Aug 31, 2020 | |
| Last Updated: | Aug 07, 2020 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Location
Participants in this study will receive ketamine infusions twice a week for 4 weeks (acute phase). Participants who respond or remit will continue with an additional 4 weeks of weekly ketamine infusions (continuation phase). Participants will be assessed at baseline, end of acute phase, and end of continuation phase for effectiveness, safety, and executive functioning. Participants will be asked to complete daily surveys of their depression symptoms during their participation.
Eligibility Criteria
| Sex: | All |
|---|---|
| Minimum Age: | 65 |
More Details
| NCT Number: | NCT04504175 |
|---|---|
| Other IDs: | 202007085 |
| Study URL: | https://ClinicalTrials.gov/show/NCT04504175 |
Last updated: Jan 27, 2021